Ingenol mebutate versus imiquimod versus diclofenac for actinic cheilitis: a 6-month follow-up clinical study

Clin Exp Dermatol. 2019 Mar;44(2):231-234. doi: 10.1111/ced.13763. Epub 2018 Sep 21.

Authors

H Husein-ElAhmed¹, F M Almazan-Fernandez², S Husein-ElAhmed¹

Affiliations

¹ Department of Dermatology, Hospital General de Baza, Avenida Murcia S/N, CP 18800, Granada, Spain.
² Department of Dermatology, Hospital Hospitalario San Cecilio, Granada, Spain.

PMID: 30242791
DOI: 10.1111/ced.13763

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Aged
Aged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antineoplastic Agents / therapeutic use
Cheilitis / drug therapy*
Diclofenac / therapeutic use*
Diterpenes / therapeutic use*
Female
Follow-Up Studies
Humans
Imiquimod / therapeutic use*
Male
Middle Aged

Substances

3-ingenyl angelate
Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Diterpenes
Diclofenac
Imiquimod

Supplementary concepts

Actinic cheilitis